indomethacin has been researched along with Cancer of Prostate in 26 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2." | 1.39 | Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. ( Adeniji, AO; Byrns, MC; Chen, M; Christianson, DW; Jin, Y; Liedtke, AJ; Marnett, LJ; Penning, TM, 2013) |
| "Adrenal androgens can be metabolized by prostate cancer cells, which is one of the mechanisms associated with progression to castration-resistant prostate cancer (CRPC)." | 1.39 | Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. ( Brandt, A; Hamid, AR; Pfeiffer, MJ; Schaafsma, E; Schalken, JA; Sedelaar, JP; Sweep, FC; Verhaegh, GW, 2013) |
| "Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen deprivation therapy of primary prostate cancer can be mediated by reactivation of the androgen receptor (AR)." | 1.37 | Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. ( Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H, 2011) |
| "MK886 killed prostate cancer PC3 cells only at the higher, toxic concentration (10 microM), whereas the lower concentration (1 microM) had no major effect on cell survival." | 1.31 | Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. ( Bernardi, P; Colonna, R; Cusan, C; Gugliucci, A; Mancini, M; Pagano, F; Petronilli, V; Prato, M; Ranzato, L; Scorrano, L, 2002) |
| "Concerning the effect of rTNF on metastasis, we found that the metastasis to lung was promoted by 1 x 10(5) units of rTNF and the promotion of metastasis was restricted by indomethacin." | 1.29 | Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MAT-LyLu prostatic cancer. ( Iizumi, T; Soma, GI; Umeda, T; Yazaki, T, 1993) |
| "The DU 145 human prostate cancer cell line, which is also androgen-unresponsive, showed no growth response to LA and was less susceptible to growth inhibition when cultured in the presence of omega-3 FAs." | 1.28 | Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. ( Connolly, JM; Rose, DP, 1991) |
| "When 12 patients with basal and/or squamous cell carcinomas of the facial areas were studied, the macrophages from 2 of these patients possessed cytotoxic macrophages." | 1.27 | The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. ( Cameron, DJ; Stromberg, BV, 1984) |
| "Tumor volume, metastasis, and determination of regression of primary tumor have been evaluated." | 1.27 | Nb rat prostate adenocarcinoma model androgen-sensitive tumor: metastasis control. ( Drago, JR; Fralisch, A; Weed, P, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridoux, A | 1 |
| Millet, R | 1 |
| Pommery, J | 1 |
| Pommery, N | 1 |
| Henichart, JP | 1 |
| Lee, JY | 1 |
| Kim, JK | 1 |
| Cho, MC | 1 |
| Shin, S | 1 |
| Yoon, DY | 1 |
| Heo, YS | 1 |
| Kim, Y | 1 |
| Liedtke, AJ | 1 |
| Adeniji, AO | 1 |
| Chen, M | 1 |
| Byrns, MC | 1 |
| Jin, Y | 1 |
| Christianson, DW | 1 |
| Marnett, LJ | 1 |
| Penning, TM | 1 |
| Liu, C | 2 |
| Yang, JC | 2 |
| Armstrong, CM | 1 |
| Lou, W | 2 |
| Liu, L | 1 |
| Qiu, X | 1 |
| Zou, B | 1 |
| Lombard, AP | 1 |
| D'Abronzo, LS | 1 |
| Evans, CP | 2 |
| Gao, AC | 2 |
| Zhu, Y | 1 |
| Nadiminty, N | 1 |
| Gaikwad, NW | 1 |
| Sun, SQ | 1 |
| Gu, X | 1 |
| Gao, XS | 1 |
| Li, Y | 2 |
| Yu, H | 2 |
| Xiong, W | 1 |
| Wang, W | 1 |
| Teng, Y | 1 |
| Zhou, D | 1 |
| Lincová, E | 1 |
| Hampl, A | 1 |
| Pernicová, Z | 1 |
| Starsíchová, A | 1 |
| Krcmár, P | 1 |
| Machala, M | 2 |
| Kozubík, A | 1 |
| Soucek, K | 1 |
| Cai, C | 1 |
| Chen, S | 2 |
| Ng, P | 1 |
| Bubley, GJ | 1 |
| Nelson, PS | 1 |
| Mostaghel, EA | 1 |
| Marck, B | 1 |
| Matsumoto, AM | 1 |
| Simon, NI | 1 |
| Wang, H | 1 |
| Balk, SP | 1 |
| Hamid, AR | 1 |
| Pfeiffer, MJ | 1 |
| Verhaegh, GW | 1 |
| Schaafsma, E | 1 |
| Brandt, A | 1 |
| Sweep, FC | 1 |
| Sedelaar, JP | 1 |
| Schalken, JA | 1 |
| Sovak, M | 1 |
| Seligson, AL | 1 |
| Konas, M | 1 |
| Hajduch, M | 1 |
| Dolezal, M | 1 |
| Nagourney, R | 1 |
| L'Allemain, G | 1 |
| Nithipatikom, K | 1 |
| Isbell, MA | 1 |
| Lindholm, PF | 1 |
| Kajdacsy-Balla, A | 1 |
| Kaul, S | 1 |
| Campell, WB | 1 |
| Cameron, DJ | 1 |
| Stromberg, BV | 1 |
| Drago, JR | 2 |
| Weed, P | 1 |
| Fralisch, A | 1 |
| Reid, J | 1 |
| Schrader, AP | 1 |
| Morris, BJ | 1 |
| Iizumi, T | 1 |
| Yazaki, T | 1 |
| Umeda, T | 1 |
| Soma, GI | 1 |
| Kawabe, M | 1 |
| Shibata, MA | 1 |
| Sano, M | 1 |
| Takesada, Y | 1 |
| Tamano, S | 1 |
| Ito, N | 1 |
| Shirai, T | 1 |
| Kasof, GM | 1 |
| Lu, JJ | 1 |
| Liu, D | 1 |
| Speer, B | 1 |
| Mongan, KN | 1 |
| Gomes, BC | 1 |
| Lorenzi, MV | 1 |
| Andrews, P | 1 |
| Krygier, S | 1 |
| Djakiew, D | 1 |
| Gugliucci, A | 1 |
| Ranzato, L | 1 |
| Scorrano, L | 1 |
| Colonna, R | 1 |
| Petronilli, V | 1 |
| Cusan, C | 1 |
| Prato, M | 1 |
| Mancini, M | 1 |
| Pagano, F | 1 |
| Bernardi, P | 1 |
| Pollard, M | 1 |
| Chang, CF | 1 |
| Luckert, PH | 1 |
| Petrini, B | 1 |
| Wolk, G | 1 |
| Wasserman, J | 1 |
| Vedin, I | 1 |
| Strannegård, O | 1 |
| Blomgren, H | 1 |
| Esposti, PL | 1 |
| Rose, DP | 1 |
| Connolly, JM | 1 |
| Lahat, N | 1 |
| Alexander, B | 1 |
| Levin, DR | 1 |
| Moskovitz, B | 1 |
| Anderson, KM | 1 |
| Wygodny, JB | 1 |
| Ondrey, F | 1 |
| Harris, J | 1 |
| Lombard, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer[NCT00798876] | 56 participants (Actual) | Interventional | 2001-12-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 other studies available for indomethacin and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Cell Line, Tumor; Cell Proliferation; Cyclooxyg | 2010 |
Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor gamma on human cervical and prostate cancer cells.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Flavonoids; HeLa Cells; Humans; Mal | 2010 |
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Catalytic Domain; Enzyme In | 2013 |
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Topics: Administration, Oral; Aldo-Keto Reductase Family 1 Member C3; Alternative Splicing; Animals; Benzami | 2019 |
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Age | 2015 |
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Topics: Aldo-Keto Reductase Family 1 Member C3; Cell Line, Tumor; Cell Proliferation; Dinoprost; Drug Resist | 2016 |
Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cel | 2009 |
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cel | 2011 |
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Apoptosis; Biomarkers, Tumo | 2013 |
Herbal composition PC-SPES for management of prostate cancer: identification of active principles.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents, Hormonal; Antineopla | 2002 |
[Beware of magic pills].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents, Phytogenic; Drug and | 2002 |
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Arachidonic Acid; Cyclooxygenase 1; Cyclooxygenase 2; | 2002 |
The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity.
Topics: Carcinoma, Squamous Cell; Cell Line; Cytotoxicity, Immunologic; Facial Neoplasms; Female; Head and N | 1984 |
Nb rat prostate adenocarcinoma model androgen-sensitive tumor: metastasis control.
Topics: Adenocarcinoma; Animals; Castration; Cyclophosphamide; Disease Models, Animal; Heparin; Indomethacin | 1983 |
No effect of kinins on DNA synthesis in LNCaP prostate cancer cells.
Topics: Adenocarcinoma; Bradykinin Receptor Antagonists; Dihydrotestosterone; DNA, Neoplasm; Drug Interactio | 1994 |
Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MAT-LyLu prostatic cancer.
Topics: Adenocarcinoma; Animals; Dinoprostone; Humans; Indomethacin; Lung Neoplasms; Male; Neoplasm Metastas | 1993 |
Decrease of prostaglandin E2 and 5-bromo-2'-deoxyuridine labeling but not prostate tumor development by indomethacin treatment of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate.
Topics: Aminobiphenyl Compounds; Animals; Body Weight; Bromodeoxyuridine; Dinoprostone; DNA; Indomethacin; M | 1997 |
Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; bcl-X Protein; Chromosome Mapping; Chromosomes, | 2001 |
Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclooxygenase 2; Cyclooxygenase | 2002 |
Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors.
Topics: Animals; Arachidonic Acid; Cell Death; Cell Line; Cell Membrane Permeability; Cell Survival; Dose-Re | 2002 |
Investigations on prostatic adenocarcinomas in rats.
Topics: Adenocarcinoma; Anesthetics; Animals; Aspirin; Cell Line; Female; Immunotherapy; Indomethacin; Lung | 1977 |
Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer.
Topics: Aged; Escherichia coli; Female; Humans; Indomethacin; Interleukin-1; Lipopolysaccharides; Male; Midd | 1991 |
Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines.
Topics: Cell Division; Eicosanoids; Fatty Acids; Humans; Indomethacin; Linoleic Acid; Linoleic Acids; Male; | 1991 |
The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Cimetidine; Cytotoxicity, Immunologic; Humans; Indomethacin; Interleukin-2; Ki | 1989 |
Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Adenocarcinoma; Arachidonic Acid; Arachidonic Acids; Calcimycin; Cy | 1988 |
Metastasis in the androgen-insensitive Nb rat prostatic carcinoma system.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cortisone; Disease Models, Animal; Drug Therapy, Com | 1985 |